<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Stilbazulenyl nitrone (STAZN) is a potent <z:chebi fb="11" ids="22586">antioxidant</z:chebi> that, in a rat model of transient focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo>, confers significant enduring functional and morphological neuroprotection </plain></SENT>
<SENT sid="1" pm="."><plain>This study investigated the influence of dose and time of administration on the neuroprotective effects of STAZN in the intraluminal suture model of middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (MCAo) </plain></SENT>
<SENT sid="2" pm="."><plain>Dose response: At 2 and 4 h after the <z:hpo ids='HP_0003674'>onset</z:hpo> of MCAo, animals received intravenously either STAZN (low dose=0.07 mg/kg, n=8; medium dose=0.7 mg/kg, n=9; high dose=3.5 mg/kg, n=9), an equivalent volume of vehicle (30% Solutol HS15 and 70% isotonic saline, 0.37 ml/kg, n=5) or saline (0.37 ml/kg, n=5) </plain></SENT>
<SENT sid="3" pm="."><plain>Only the medium dose improved scores (p&lt;0.05) on a standardized neurobehavioral test at 1, 2 and 3 days after MCAo </plain></SENT>
<SENT sid="4" pm="."><plain>Only the medium dose reduced the total infarction (51%, p=0.014) compared to controls </plain></SENT>
<SENT sid="5" pm="."><plain>These results indicate that STAZN exhibits maximal neuroprotection at the 0.7 mg/kg dose </plain></SENT>
<SENT sid="6" pm="."><plain>Therapeutic window: STAZN (0.6 mg/kg) dissolved in <z:chebi fb="0" ids="28262">dimethylsulfoxide</z:chebi> was given intra-peritoneally at 2 and 4 h (n=11), 3 and 5 h (n=10), 4 and 6 h (n=10) or 5 and 7 h (n=7) after the <z:hpo ids='HP_0003674'>onset</z:hpo> of MCAo </plain></SENT>
<SENT sid="7" pm="."><plain>Additional doses were given at 24 and 48 h </plain></SENT>
<SENT sid="8" pm="."><plain>Vehicle (<z:chebi fb="0" ids="28262">dimethylsulfoxide</z:chebi>, 2.0 ml/kg, n=6) was administered at 3, 5, 24 and 48 h </plain></SENT>
<SENT sid="9" pm="."><plain>STAZN treatment initiated at 2 or 3 h after the <z:hpo ids='HP_0003674'>onset</z:hpo> of MCAo improved neurological scores (p&lt;0.001) and reduced total infarction (42.2%, p&lt;0.05) compared to controls </plain></SENT>
</text></document>